The challenges are now to determine whether other CXCR2 ligands exert a significant influence on these processes despite lower expression levels, to elucidate the precise functions of granulocytes in demyelinating diseases, and to translate this knowledge into new therapeutic strategies for multiple sclerosis. This evidence concerns the gene CXCR2 and multiple sclerosis.